Patrick J. Mcenany - Feb 15, 2023 Form 4 Insider Report for CATALYST PHARMACEUTICALS, INC. (CPRX)

Role
President and CEO, Director
Signature
/s/ Patrick J. McEnany
Stock symbol
CPRX
Transactions as of
Feb 15, 2023
Transactions value $
$0
Form type
4
Date filed
2/17/2023, 04:01 PM
Previous filing
Dec 30, 2022
Next filing
May 17, 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CPRX Common Stock, par value $0.001 per share Options Exercise +58.3K +1.5% 3.96M Feb 15, 2023 Direct F1
transaction CPRX Common Stock, par value $0.001 per share Tax liability -14.2K -0.36% 3.95M Feb 15, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CPRX Restricted Stock Units Options Exercise $0 -58.3K -1.83% $0.00 3.13M Feb 15, 2023 Common Stock 58.3K Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.
F2 Shares withheld by the Registrant to satisfy applicable withholding taxes upon vesting of restricted stock units.
F3 Derivative securities vest in equal tranches, 1/3rd on February 14, 2023, 1/3rd on February 14, 2024 and 1/3rd on February 14, 2025.
F4 Shares of common stock are required to be delivered to the Reporting Person within sixty days of vesting. The first tranche of shares was delivered on February 15, 2023.